PH30121A - Retroviral protease inhibitors - Google Patents

Retroviral protease inhibitors

Info

Publication number
PH30121A
PH30121A PH47454A PH47454A PH30121A PH 30121 A PH30121 A PH 30121A PH 47454 A PH47454 A PH 47454A PH 47454 A PH47454 A PH 47454A PH 30121 A PH30121 A PH 30121A
Authority
PH
Philippines
Prior art keywords
protease inhibitors
retroviral protease
retroviral
inhibitors
protease
Prior art date
Application number
PH47454A
Other languages
English (en)
Inventor
Michael Peter Trova
Robert E Babine
Nan Zhang
Steven R Schow
Allan Wissner
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of PH30121A publication Critical patent/PH30121A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/22—Oxygen atoms attached in position 2 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/022—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
PH47454A 1992-12-16 1993-12-15 Retroviral protease inhibitors PH30121A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/991,876 US5430150A (en) 1992-12-16 1992-12-16 Retroviral protease inhibitors

Publications (1)

Publication Number Publication Date
PH30121A true PH30121A (en) 1996-12-27

Family

ID=25537673

Family Applications (1)

Application Number Title Priority Date Filing Date
PH47454A PH30121A (en) 1992-12-16 1993-12-15 Retroviral protease inhibitors

Country Status (17)

Country Link
US (1) US5430150A (fi)
EP (1) EP0602306A1 (fi)
JP (1) JPH07330733A (fi)
KR (1) KR940014332A (fi)
CN (1) CN1097192A (fi)
AU (1) AU673693B2 (fi)
CA (1) CA2111454A1 (fi)
CZ (1) CZ252693A3 (fi)
FI (1) FI935644A (fi)
HU (1) HUT65708A (fi)
IL (1) IL108006A0 (fi)
MX (1) MX9305364A (fi)
NO (1) NO934628L (fi)
NZ (1) NZ250418A (fi)
PH (1) PH30121A (fi)
TW (1) TW223630B (fi)
ZA (1) ZA939432B (fi)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413999A (en) * 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
WO1993018006A1 (en) 1992-03-11 1993-09-16 Narhex Limited Amine derivatives of oxo- and hydroxy-substitued hydrocarbons
US6071895A (en) 1992-03-11 2000-06-06 Narhex Limited Polar-substituted hydrocarbons
US5888992A (en) 1992-03-11 1999-03-30 Narhex Limited Polar substituted hydrocarbons
EP0812857A1 (en) * 1994-12-08 1997-12-17 LG Chemical Limited Irreversible HIV protease inhibitors, compositions containing same and process for the preparation thereof
US5470979A (en) * 1994-07-01 1995-11-28 American Cyanamid Company Asymmetric synthesis of bicyclic amino acid esters
ES2148518T3 (es) * 1994-08-03 2000-10-16 Kumiai Chemical Industry Co Derivado amida de aminoacido, procedimiento para su produccion, fungicida agrohorticola y metodo fungicida.
US6329139B1 (en) 1995-04-25 2001-12-11 Discovery Partners International Automated sorting system for matrices with memory
US6017496A (en) 1995-06-07 2000-01-25 Irori Matrices with memories and uses thereof
US6518292B1 (en) 1999-03-12 2003-02-11 Bristol-Myers Squibb Co. Heterocyclic aromatic compounds usefuls as growth hormone secretagogues
US6525203B1 (en) 1999-03-12 2003-02-25 Bristol-Myers Squibb Company Heterocyclic aromatic compounds useful as growth hormone secretagogues
TWI290136B (en) * 2000-04-05 2007-11-21 Daiichi Seiyaku Co Ethylenediamine derivatives
WO2003000680A1 (fr) * 2001-06-20 2003-01-03 Daiichi Pharmaceutical Co., Ltd. Derives de diamine
WO2003016302A1 (fr) * 2001-08-09 2003-02-27 Daiichi Pharmaceutical Co., Ltd. Derives de diamine
WO2003000657A1 (fr) * 2001-06-20 2003-01-03 Daiichi Pharmaceutical Co., Ltd. Derives de diamine
MY139563A (en) * 2002-09-04 2009-10-30 Bristol Myers Squibb Co Heterocyclic aromatic compounds useful as growth hormone secretagogues
CA2511493A1 (en) * 2002-12-25 2004-07-15 Daiichi Pharmaceutical Co., Ltd. Diamine derivatives
JO3794B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
JO3793B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv مثبطات تيروزين كاينيز بروتون وأساليب استخدامها

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5142056A (en) * 1989-05-23 1992-08-25 Abbott Laboratories Retroviral protease inhibiting compounds
IL89900A0 (en) * 1988-04-12 1989-12-15 Merck & Co Inc Hiv protease inhibitors useful for the treatment of aids and pharmaceutical compositions containing them
IL91307A0 (en) * 1988-08-24 1990-03-19 Merck & Co Inc Hiv protease inhibitors and pharmaceutical compositions for the treatment of aids containing them
US5151438A (en) * 1989-05-23 1992-09-29 Abbott Laboratories Retroviral protease inhibiting compounds
US5126326A (en) * 1989-06-06 1992-06-30 Bio-Mega, Inc. Enzyme inhibiting peptide derivatives
GB8927913D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
CA2032259A1 (en) * 1989-12-18 1991-06-19 Wayne J. Thompson Hiv protease inhibitors useful for the treatment of aids
CA2052907A1 (en) * 1990-10-11 1992-04-12 Joseph P. Vacca Hiv protease inhibitors having symmetrical structure
EP0492136A3 (en) * 1990-12-20 1993-05-26 American Cyanamid Company Retroviral protease inhibitors derived from 3-chloro-2-chloromethyl-1-propene
AU3069192A (en) * 1991-11-01 1993-06-07 Smithkline Beecham Corporation Hiv protease inhibitors containing guanidine
EP0541168B1 (en) * 1991-11-08 1998-03-11 Merck & Co. Inc. HIV protease inhibitors useful for the treatment of aids

Also Published As

Publication number Publication date
NO934628L (no) 1994-06-17
HU9303603D0 (en) 1994-04-28
CZ252693A3 (en) 1994-07-13
IL108006A0 (en) 1994-04-12
FI935644A0 (fi) 1993-12-15
NZ250418A (en) 1995-04-27
JPH07330733A (ja) 1995-12-19
NO934628D0 (no) 1993-12-15
ZA939432B (en) 1994-08-09
KR940014332A (ko) 1994-07-18
TW223630B (en) 1994-05-11
FI935644A (fi) 1994-06-17
US5430150A (en) 1995-07-04
HUT65708A (en) 1994-07-28
EP0602306A1 (en) 1994-06-22
CN1097192A (zh) 1995-01-11
AU673693B2 (en) 1996-11-21
AU5069993A (en) 1994-06-30
MX9305364A (es) 1994-06-30
CA2111454A1 (en) 1994-06-17

Similar Documents

Publication Publication Date Title
EP0580402A3 (en) Aminediol protease inhibitors
ZA915269B (en) Retroviral protease inhibitors
IL90218A0 (en) Retroviral protease inhibitors
HU9601508D0 (en) Dp-iv-serine protease inhibitors
KR100190517B1 (en) Hiv protease inhibitors
IL102534A0 (en) Retroviral protease inhibitors
ZA929869B (en) Hiv protease inhibitors
EP0428849A3 (en) Retroviral protease inhibitors
IL108006A0 (en) Retroviral protease inhibitors
ZA899558B (en) Retroviral protease inhibitors
ZA915271B (en) Inhibitors of retroviral proteases
IL100161A0 (en) Retroviral protease inhibitors derived from 3-chloro-2-chloro-methyl-1-propene
EP0628035A4 (en) RETROVIRAL PROTEASE INHIBITORS.
EP0566237A3 (en) Retroviral protease inhibitors.
EP0575500A4 (en) Hiv protease inhibitors
ZA939480B (en) Enzyme inhibitor
IL105450A0 (en) Hydroxy-carbamate retroviral protease inhibitors
IL100085A0 (en) Retroviral protease inhibitors
IL100083A0 (en) Retroviral protease inhibitors
ZA925360B (en) Retroviral protease inhibitors.
ZA935243B (en) Aminedediol protease inhibitors
ZA924089B (en) Novel thrombin inhibitors
IE894013L (en) Retroviral protease inhibitors
HU9502451D0 (en) Combinations of retroviral inhibitors
GB9323850D0 (en) Protease inhibitors